Meeting
2016 Gastrointestinal Cancers Symposium
Early tumor shrinkage as a predictor of favorable outcomes in patients (pts) with advanced pancreatic cancer treated with FOLFIRINOX.
Authors
Yasuhiro Kaga
Division of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan
Yasuhiro Kaga , Yu Sunakawa , Yutaro Kubota , Teppei Tagawa , Taikan Yamamoto , Toshikazu Ikusue , Yu Uto , Yu Kitahara , Hirokazu Toshima , Kouji Kobayashi , Atsushi Hisamatsu , Wataru Ichikawa , Takashi Sekikawa , Ken Shimada , Yasutsuna Sasaki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 237)
DOI
10.1200/jco.2016.34.4_suppl.237
Abstract #
237
Poster Bd #
C3
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy.
First Author: Thomas H. Cartwright
Poster
2013 ASCO Annual Meeting
Updated use of first-line chemotherapy for advanced pancreatic cancer: Folfirinox versus gemcitabine.
First Author: Thomas H. Cartwright
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.
First Author: Bomi Kim
Poster
2018 ASCO Quality Care Symposium
Treatment patterns, toxicity, and outcomes of elderly patients with advanced pancreatic cancer receiving first-line chemotherapy.
First Author: Robert Kudlovich